Recent Updates
Recently added Catalysts

Naprelan

Phase 1

Pharmacokinetics | Small molecule | Other |Bayer AG|Last Updated: May 20, 2014

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment28

FDA Designations

No designations recorded

Clinical trial landscape

Naprelan · 1 trial · 1 indication

Phase 1 1
NCT00969449Pharmacokinetics Study Comparing Naproxen Sodium Extended Release and NaprelanPharmacokinetics
COMPLETED28 Analytics
PHASE1COMPLETED
Pharmacokinetics Study Comparing Naproxen Sodium Extended Release and Naprelan
PharmacokineticsUnlock trial analytics

Study Endpoints

Primary Endpoints

Pharmacokinetic profile of Naproxen Sodium ER 660 mg compared to Naprelan
36 hours

Secondary Endpoints

To assess safety and tolerability of the extended release naproxen sodium
36 hours
To assess additional pharmacokinetic parameters
36 hours
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Arm 1EXPERIMENTAL -
Arm 2ACTIVE_COMPARATOR -

Interventions

NameTypeDescription
Naproxen Sodium, (BAY H6689)DRUGOne dose of Naproxen sodium extended release 660 mg under fasting conditions
Naprelan, (BAY H6689)DRUGOne dose of Naprelan 500 mg (2 tablets) under fasting conditions
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Healthy male and female subjects between 18 to 55 years of age inclusive with a Body Mass Index (BMI) of approximately 18 to 30 kg/m2; and a total body weight \>50 kg (110 lbs) * Results of screening and clinical laboratory tests are within normal range or considered not clini...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about Naprelan

What is Naprelan used for?

Naprelan is a small molecule drug being studied for pharmacokinetics, which is the study of how the drug is absorbed, distributed, metabolized, and eliminated in the body. It is currently in Phase 1 clinical development for this indication.

What does Naprelan target?

Naprelan does not have a specified molecular target or target class. It is a small molecule drug being investigated for pharmacokinetics, meaning the focus of its clinical study is on how the body processes the drug rather than on a specific biological target.

Who makes Naprelan?

Naprelan is being developed by Bayer AG, a multinational pharmaceutical company. Bayer AG is publicly traded under the ticker symbol BAYRY.

What phase is Naprelan in?

Naprelan is in Phase 1 clinical development. It has completed one Phase 1 trial, and there are no active trials currently ongoing. The drug is investigational and has not been approved for any use.

What clinical trials is Naprelan in?

Naprelan has one completed clinical trial, identified by the NCT number NCT00969449. This was a Phase 1 study titled 'Pharmacokinetics Study Comparing Naproxen Sodium Extended Release and Naprelan,' which enrolled 28 participants in the United States.

Is Naprelan the same as naproxen sodium extended release?

Naprelan is being studied in comparison to naproxen sodium extended release in a clinical trial. The trial NCT00969449 was designed to compare the pharmacokinetics of the two formulations, but it is not stated that they are the same drug.